CG Oncology

Historical price data

CG Oncology is a late-stage biopharma company with a mission to deliver innovative, bladder-sparing immunotherapies for patients with non-muscle invasive bladder cancer (NMIBC). Its lead asset, cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy, has garnered FDA Fast Track and Breakthrough Therapy designations and is in a pivotal Phase 3 program. The company's strategy is intensely focused on successfully commercializing this potential backbone therapy in a significant market with limited effective options for BCG-unresponsive patients.

Engineered oncolytic immunotherapy (OIT) platform based on an intravesically delivered adenovirus designed for selective cancer cell lysis and induction of a systemic anti-tumor immune response.

The NMIBC competitive landscape is defined by the entrenched standard BCG, the approved gene therapy nadofaragene firadenovec, and systemic checkpoint inhibitors. CG Oncology's cretostimogene differentiates through its dual oncolytic/immunotherapeutic mechanism and intravesical delivery. Near-term competition is limited, but several earlier-stage novel therapies are in development.